Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 7:02 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 85 matching trials from the live ClinicalTrials.gov search.
Recruiting No phase listed Observational Accepts healthy volunteers

The CurePSP Genetics Program

NCT06647641
Conditions
PSP, PSP - Progressive Supranuclear Palsy, Corticobasal Syndrome, Corticobasal Syndrome(CBS), Corticobasal Degeneration Syndrome, Corticobasal Degeneration, Corticobasal Degeneration (CBD), Corticobasal Syndrome (CBS), MSA, MSA - Multiple System Atrophy, MSA-C, Multiple System Atrophy, Multiple System Atrophy (MSA) With Orthostatic Hypotension, Multiple System Atrophy - Cerebellar Subtype (MSA-C), Multiple System Atrophy - Parkinsonian Subtype (MSA-P), Multiple System Atrophy, Cerebellar Type, Multiple System Atrophy, Parkinsonian Type, Progressive Supranuclear Palsy, Progressive Supranuclear Palsy(PSP), Progressive Supranuclear Palsy (PSP)
Interventions
Whole genome sequencing will be performed at the NIH
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
35 Years and older
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2030
U.S. locations
1
States / cities
Boston, Massachusetts
Completed Early Phase 1 Interventional Accepts healthy volunteers

Tau Imaging With JNJ067

NCT03926702
Conditions
Alzheimer Disease, Mild Cognitive Impairment, Progressive Supranuclear Palsy
Interventions
Radiopharmaceuticals
Drug
Lead sponsor
University of California, Berkeley
Other
Eligibility
50 Years and older
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Berkeley, California
Conditions
Parkinson Disease, Multiple System Atrophy, Progressive Supranuclear Palsy
Interventions
Not listed
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
Not listed
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2026
U.S. locations
1
States / cities
Dallas, Texas
Conditions
Progressive Supranuclear Palsy
Interventions
Placebo, ABBV-8E12
Drug
Lead sponsor
AbbVie
Industry
Eligibility
40 Years and older
Enrollment
378 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
27
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Beverly Hills, California + 22 more
Conditions
Progressive Supranuclear Palsy
Interventions
TPN-101, 100 mg/day, TPN-101, 200 mg/day, TPN-101, 400 mg/day, Placebo
Drug
Lead sponsor
Transposon Therapeutics, Inc.
Industry
Eligibility
41 Years to 86 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
14
States / cities
Phoenix, Arizona • La Jolla, California • San Francisco, California + 11 more
Completed No phase listed Observational

Speech Accessibility Project

NCT05889260
Conditions
Parkinson Disease, Progressive Supranuclear Palsy, Multiple System Atrophy, Dementia With Lewy Bodies
Interventions
Not listed
Lead sponsor
University of Illinois at Urbana-Champaign
Other
Eligibility
18 Years and older
Enrollment
485 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
2
States / cities
Denver, Colorado • Urbana, Illinois
Conditions
Progressive Supranuclear Palsy
Interventions
Davunetide, Placebo
Drug
Lead sponsor
Allon Therapeutics
Industry
Eligibility
41 Years to 85 Years
Enrollment
313 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
28
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 24 more
Conditions
PSP - Progressive Supranuclear Palsy
Interventions
LM11A-31, Matching Placebo
Drug
Lead sponsor
Adam Boxer
Other
Eligibility
41 Years to 86 Years
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
San Francisco, California
Conditions
Progressive Supranuclear Palsy, Parkinson Disease, MSA - Multiple System Atrophy
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 89 Years
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
Baltimore, Maryland • Boston, Massachusetts
Conditions
Dementia-related Psychosis
Interventions
Placebo, Pimavanserin 34 mg, Pimavanserin 20 mg
Drug
Lead sponsor
ACADIA Pharmaceuticals Inc.
Industry
Eligibility
50 Years to 90 Years
Enrollment
392 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
27
States / cities
Costa Mesa, California • Fullerton, California • Aventura, Florida + 22 more
Conditions
Progressive Supranuclear Palsy, PSP, Neurodegenerative Diseases, Atypical Parkinsonism
Interventions
AMX0035, Placebo
Drug · Other
Lead sponsor
Amylyx Pharmaceuticals Inc.
Industry
Eligibility
40 Years to 80 Years
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
35
States / cities
Scottsdale, Arizona • Little Rock, Arkansas • Fountain Valley, California + 31 more
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Gait Analysis in Neurological Disease

NCT02994719
Conditions
Parkinson's Disease, Parkinsonian Disorders, Atypical Parkinson Disease, Progressive Supranuclear Palsy, Multiple System Atrophy, Corticobasal Degeneration, Gait, Frontal, Huntington Disease, Ataxia, Spinocerebellar
Interventions
Anti-Parkinson medication, Deep Brain Stimulation
Drug · Device
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 85 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Progressive Supranuclear Palsy(PSP), Insomnia
Interventions
Suvorexant, Zolpidem, Placebo oral capsule
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
San Francisco, California
Conditions
Progressive Supranuclear Palsy (PSP)
Interventions
ABBV-8E12
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
2
States / cities
La Jolla, California • Dallas, Texas
Conditions
PSP - Progressive Supranuclear Palsy
Interventions
AADvac1, Matching Placebo
Biological
Lead sponsor
Adam Boxer
Other
Eligibility
41 Years to 86 Years
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
San Francisco, California
Completed No phase listed Observational Accepts healthy volunteers

4-Repeat Tauopathy Neuroimaging Initiative - Cycle 2

NCT02966145
Conditions
Corticobasal Degeneration (CBD), Corticobasal Syndrome (CBS), Cortical-basal Ganglionic Degeneration (CBGD), Progressive Supranuclear Palsy (PSP), Nonfluent Variant Primary Progressive Aphasia (nfvPPA), Oligosymptomatic/Variant Progressive Supranuclear Palsy (o/vPSP)
Interventions
Observational Study
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
40 Years to 80 Years
Enrollment
293 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2024
U.S. locations
7
States / cities
San Diego, California • San Francisco, California • Baltimore, Maryland + 4 more
Conditions
Progressive Supranuclear Palsy
Interventions
GDNF & Synchro Med Infusion System
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
Not listed
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Recruiting Not applicable Interventional

Neurologic Stem Cell Treatment Study

NCT02795052
Conditions
Neurologic Disorders, Nervous System Diseases, Neurodegenerative Diseases, Neurological Disorders, Stroke, Traumatic Brain Injury, Cadasil, Chronic Traumatic Encephalopathy, Cerebral Infarction, Cerebral Ischemia, Cerebral Stroke, Cerebral Hemorrhage, Parkinson, Multi-System Degeneration, MSA - Multiple System Atrophy, Progressive Supranuclear Palsy, ALS, Amyotrophic Lateral Sclerosis, Neuropathy, Diabetic Neuropathies, Alzheimer Disease, Dementia, Frontotemporal Dementia, Lewy Body Disease, Cognitive Impairment, Lewy Body Variant of Alzheimer Disease
Interventions
Intravenous and Intranasal BMSC
Procedure
Lead sponsor
MD Stem Cells
Industry
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2028
U.S. locations
2
States / cities
Westport, Connecticut • Coral Springs, Florida
Conditions
Supranuclear Palsy, Progressive
Interventions
BIIB092
Drug
Lead sponsor
Biogen
Industry
Eligibility
41 Years to 86 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
13
States / cities
Birmingham, Alabama • La Jolla, California • Los Angeles, California + 10 more
Recruiting No phase listed Observational Accepts healthy volunteers

ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD)

NCT04363684
Conditions
Frontotemporal Lobar Degeneration (FTLD), Progressive Supranuclear Palsy (PSP), Corticobasal Degeneration (CBD), Behavioral Variant Frontotemporal Dementia (bvFTD), Semantic Variant Primary Progressive Aphasia (svPPA), Nonfluent Variant Primary Progressive Aphasia (nfvPPA), FTD With Amyotrophic Lateral Sclerosis (FTD/ALS), Amyotrophic Lateral Sclerosis, Oligosymptomatic PSP (oPSP), C9orf72, GRN Related Frontotemporal Dementia, MAPT Gene Mutation, TBK1 Gene Mutation, Oligosymptomatic Progressive Supranuclear Palsy
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
2,100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2030
U.S. locations
25
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 21 more
Recruiting No phase listed Observational Accepts healthy volunteers

Biofluid Research on Age-Related or Inherited Neurodegeneration

NCT07798700
Conditions
Frontotemporal Degeneration (FTD), ALS (Amyotrophic Lateral Sclerosis), Primary Progressive Aphasia (PPA), Familial Frontotemporal Lobar Degeneration (fFTLD), Fronto-temporal Lobar Dementia, Dementia With Lewy Bodies (DLB), Cortical Basal Syndrome (CBS), Alzheimer's Disease (AD), Progressive Supranuclear Palsy(PSP), Parkinson's Disease (PD), Parkinson's Disease Dementia (PDD), Limbic-predominant Age-related TDP-43 Encephalopathy (LATE), Posterior Cortical Atrophy (PCA), Primary Lateral Sclerosis (PLS), Primary Muscular Atrophy (PMA)
Interventions
Not listed
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2070
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Completed Phase 2Phase 3 Interventional

Effects of Coenzyme Q10 in PSP and CBD

NCT00532571
Conditions
Progressive Supranuclear Palsy, Neurological Disorders
Interventions
CoQ10
Drug
Lead sponsor
Lahey Clinic
Other
Eligibility
40 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
Burlington, Massachusetts
Conditions
Parkinson Disease, Multiple System Atrophy, Progressive Supranuclear Palsy
Interventions
Droxidopa, Placebo Oral Tablet
Drug
Lead sponsor
Loma Linda University
Other
Eligibility
50 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Loma Linda, California
Completed No phase listed Observational Accepts healthy volunteers

Advancing Research and Treatment for Frontotemporal Lobar Degeneration (ARTFL)

NCT02365922
Conditions
FTLD, Progressive Supranuclear Palsy (PSP), Frontotemporal Dementia (FTD), Corticobasal Degeneration (CBD), PPA Syndrome, Behavioral Variant Frontotemporal Dementia (bvFTD), Semantic Variant Primary Progressive Aphasia (svPPA), Nonfluent Variant Primary Progressive Aphasia (nfvPPA), FTD With Amyotrophic Lateral Sclerosis (FTD/ALS), Amyotrophic Lateral Sclerosis (ALS), Oligosymptomatic PSP (oPSP), Corticobasal Syndrome (CBS)
Interventions
Not listed
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 85 Years
Enrollment
1,489 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2020
U.S. locations
15
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 12 more